Alpha Cognition Announces CONVERGE Real-World Evidence on ZUNVEYL®(Benzgalantamine) Use in Long-Term Care
VANCOUVER, British Columbia & GRAPEVINE, Texas — Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition,” “ACI,” or the “Company”) today announced initial results from CONVERGE, an ongoing retrospective real-world evidence evaluation using longitudinal long-term care medication-administration data. As part of the ongoing CONVERGE evidence-generation program, this analysis focused on 180-day…
VANCOUVER, British Columbia and GRAPEVINE, Texas - Alpha Cognition Inc., a pharmaceutical company listed on NASDAQ as ACOG, has unveiled preliminary findings from the CONVERGE study. This study, an ongoing investigation into real-world evidence using extensive long-term care data, concentrated on the titration process and medication combinations for residents receiving ZUNVEYL, a benzgalantamine-based drug, alongside other acetylcholinesterase inhibitors like donepezil, galantamine, and rivastigmine.
The primary goal of the CONVERGE program is to generate evidence on how these treatments are utilized in actual long-term care environments, with a focus on determining if patients achieve optimal dosing levels and how their overall medication regimens evolve over time.
The analysis encompassed a diverse group of long-term care residents, including those who had never been prescribed an acetylcholinesterase inhibitor (AChEI) before, as well as individuals who were switching from another AChEI treatment.
Written by urgent.news from Financial Post's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
